Follow-up and Outcome of Operative Treatment With Decompressive Release Of The Peroneal Nerve

Not Applicable

Recruiting

• Conditions: Peroneal Nerve Entrapment
• Interventions: Procedure: Neurolysis peroneal nerve; Other: Maximal physiotherapy

• Registration Number: NCT04695834
• Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Brief Summary

The FOOT DROP trial is a prospective, multi-center, randomized controlled trial to assess if decompressive surgery for peroneal nerve entrapment is superior to maximal conservative treatment.

Patients with persisting foot drop due to peroneal nerve entrapment will be randomized to either surgery or conservative treatment if foot drop persists 10 +/- 4 weeks after onset of symptoms.

Patients will be evaluated through several questionnaires, evolution of muscle strength and several types of gait assessments. Primary endpoint is the difference in distance covered during the six minute walking test between baseline and 9 months after randomization.

Detailed Description

The Foot Drop Trial is the first prospective, randomised controlled trial to investigate the treatment of foot drop in peroneal nerve entrapment. Currently, the literature consists mostly of biased retrospective case series with the exception of some small (biased) prospective case series. No comparative trials have been conducted. The goal of the trial is to assess whether foot drop due to peroneal nerve entrapment recovers better 9 months after decompressive surgery compared to maximal conservative treatment.

Patients with persisting foot drop (MRC score ankle dorsiflexion ≤ 3) after 10 +/- 4 weeks after onset of symptoms will be randomised to either decompressive surgery within 1 week after randomisation or maximal conservative treatment focussing on physiotherapy and gait rehabilitation. Blinded outcome assessors will evaluate participants at study visits 10 days (surgical group), 6 weeks, 3 months, 6 months, 9 months (primary outcome) and 18 months (extended follow-up) after randomization.

Outcome assessors will conduct several assessments to evaluate gait improvement (6-minute walk test, 10-meter walk test, Stanmore questionnaire, functional ambulation categories, ability to walk barefoot, need for foot-ankle orthosis), muscle strength (MRC score for ankle dorsiflexion, ankle eversion, hallux extension) , quality of life (EQ-5D 5L) and cost-effectiveness of both treatment strategies (work productivity and activity impairment questionnaire (WPAI), return to work, percentage of invalidity). Electrodiagnostic follow-up will be registered at 3 months and 9 months after randomization.

The primary endpoint of the foot drop trial is the difference in distance covered in meters during the six-minute walk test (6MWD) between baseline and 9 months after randomization. Time to recovery, defined as the time necessary to cover the minimal age- and sex-specific normal 6MWD AND the time necessary for foot drop recovery to an MRC-score ≥ 4 for ankle dorsiflexion is the key secondary endpoint. No cross-over to surgery is allowed before primary endpoint is reached.

The study first succesfully piloted in 6 centers in Belgium and the Netherlands and is currently starting on a large scale in 20 centers.

Study Timeline

• Study First Submitted: 2020-12-03
• Study First Submitted QC: 2021-01-04
• Study First Posted: 2021-01-05
• Study Start: 2021-04-28
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-28
• Last Update Posted: 2024-07-01
• Primary Completion: 2027-12-31
• Study Completion: 2028-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 182

Inclusion Criteria

• Written informed consent to participate in the study must be obtained from the subject or proxy / legal representative prior to initiation of any study-mandated procedure
• EDX-documented peroneal nerve entrapment with persisting (10 ± 4 weeks) foot drop (MRC-score ≤ 3)
• Imaging (ultrasound/MRI) performed to exclude a compressive mass
• Age ≥ 18 years

Exclusion Criteria

• Subjects with posttraumatic or iatrogenic peroneal nerve injury
• Subjects with peroneal neuropathy due to a compressive mass (e.g. cyst, tumour)
• Peroneal nerve entrapment at other sites than the fibular head
• Patients with mental or physical problems that incapacitate them to participate in a physiotherapy program
• Psychiatric illness
• Pregnancy
• Planned (e)migration within 1 year after randomization to another country
• Subjects with previous foot drop
• Permanently bedridden subjects
• Subjects with neurological or musculoskeletal history which could impact foot drop assessment and/or gait analysis (e.g. polyneuropathy, hereditary neuropathy with pressure palsies, critical illness polyneuropathy, previous stroke, ankle surgery, ...).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Surgical treatment	Neurolysis peroneal nerve	Patients randomized to the surgical arm will be operated within 1 week after randomization (if possible within 2 days). Neurolysis is considered standard of care.
Conservative treatment	Maximal physiotherapy	Patients that are randomized to the conservative arm of the trial. These patients will not be operated until primary endpoint is reached. If necessary, cross-over can occur after primary endpoint is reached. Conservative treatment is considered standard of care.

Primary Outcome Measures

Name	Time	Method
The difference in distance covered in meters during the six-minute walk test (6MWD) between baseline and 9 months after randomization.	9 months	Based on a literature analysis and patient feedback on the trial design, gait analysis and recovery of a normal gait pattern are crucial in the recovery of foot drop. In 90% of interviewed patients, success of treatment was related to improvement in gait. The distance covered during the six-minute walk test (6MWT) is validated and clinically used in gait analysis.; 6MWT: patients are instructed to walk as far as possible within six minutes (strokes of 30 meters of more).; The minimal age- and sex-specific normal 6MWD is defined as 82% of the applied reference equations for prediction of the 6MWD. The reference value that will be used is 6MWDpred(m) = 868.8 - (ageyears x 2.99) - (gender x 74.7). The value for gender is 0 in male subjects and 1 in female subjects.

Secondary Outcome Measures

Name	Time	Method
Time to recovery	6 weeks, 3 months, 6 months, 9 months and 18 months (after randomization)	KEY SECONDARY ENDPOINT Time to recovery is defined as: the time necessary to cover the minimal age- and sex-specific normal distance in meters during the 6-minute walking test (6MWT) AND the time necessary for foot drop recovery to an MRC-score ≥ 4 for ankle dorsiflexion.; The MRC-score is a clinical assessment of muscle strength. MRC-ranges from 0 to 5 with zero indicating no movement at all and 5 indicating normal muscle strength.; The minimal age- and sex-specific normal 6-minute walking distance (6MWD) is defined as 82% of the applied reference equations for prediction of the 6MWD. The reference value that will be used is 6MWDpred(m) = 868.8 - (ageyears x 2.99) - (gender x 74.7). The value for gender is 0 in male subjects and 1 in female subjects.
Gait assessment: Gait speed as measured by the 10-meter walk test	6 weeks, 3 months, 6 months, 9 months and 18 months (after randomization)	Walking speed is an important aspect of gait and is often used as an objective measure of functional mobility. The 10-meter walk test is a commonly used and validated tool to assess gait speed.
Ankle dorsiflexion strength as measured by the Medical Research Council score (MRC-score).	10 days (surgery), 6 weeks, 3 months, 6 months, 9 months and 18 months (after randomization))	Medical Research Council (MRC)-score as clinical assessment of muscle strength. MRC-score ranges from 0 to 5.; 0: no movement; 1. contraction of muscle, but no movement; 2. movement, but not against gravity; 3. movement against gravity, but not against resistance; 4. movement against resistance; 5. normal strength
Gait assessment: Stanmore questionnaire	6 weeks, 3 months, 6 months, 9 months and 18 months (after randomization)	The Stanmore questionnaire has been used in the literature to assess functional outcome in patients with foot drop due to peroneal nerve injury. Seven sections (pain, need for orthosis, normal shoes, functional outcome, muscle power, degree of active dorsiflexion and foot posture) add up to a sum score of 100 points.
Health economic assessment: Work Productivity and Activity Impairment Questionnaire (WPAI)	6 weeks and 6 months after randomization	Health economic aspects of foot drop will be evaluated through the Work Productivity and Activity Impairment Questionnaire (WPAI). The WPAI is widely used and validated in multiple languages.; The WPAI questionnaire consists of 6 questions with regard to professional activity during the past 7 days.
Electrodiagnostics: evolution of conduction block at the level of the fibular head	3 months and 9 months after randomization.	All patients will have repeated electrodiagnostic examinations. The evolution of the conduction block at the level of the fibular head will be documented in the eCRF.
Complications and neurologic deficits: Motor changes as assessed by the Medical Research Council Score (MRC-score) for ankle eversion	10 days (surgery), 6 weeks, 3 months, 6 months, 9 months and 18 months (after randomization)	Medical Research Council (MRC)-score as clinical assessment of muscle strength. MRC-score ranges from 0 to 5.; 0: no movement; 1. contraction of muscle, but no movement; 2. movement, but not against gravity; 3. movement against gravity, but not against resistance; 4. movement against resistance; 5. normal strength
Ankle dorsiflexion strength as measured by isometric dynamometry.	10 days (surgery), 6 weeks, 3 months, 6 months, 9 months and 18 months (after randomization))	Recovery of ankle dorsiflexion strength is essential in patients with foot drop. The use of dynamometry allows to document ankle dorsiflexion strength in an objective manner.; Patients are asked to lay in supine position, with the knees extended. The test pad of the dynamometer is placed on the dorsal head of the first metatarsal bone. The patient is instructed to perform ankle dorsiflexion with maximal muscle strength. The best of three attempts is registered. Ankle dorsiflexion is measured and reported in both ankles (in kilograms). The ankle dorsiflexion strength ratio, defined as the ratio of ankle dorsiflexion strength in the affected ankle over ankle dorsiflexion strength in the healthy ankle will be calculated and reported
Complications and neurologic deficits: Motor changes as assessed by the Medical Research Council Score (MRC-score) for hallux extension	10 days (surgery), 6 weeks, 3 months, 6 months, 9 months and 18 months (after randomization))	Medical Research Council (MRC)-score as clinical assessment of muscle strength. MRC-score ranges from 0 to 5.; 0: no movement; 1. contraction of muscle, but no movement; 2. movement, but not against gravity; 3. movement against gravity, but not against resistance; 4. movement against resistance; 5. normal strength
Gait assessment: Difference in distance covered in meters during the six-minute walk test	6 weeks, 3 months, 6 months and 18 months (after randomization)	The distance covered during the six-minute walk test (6MWT) is validated and clinically used in gait analysis.; 6MWT: patients are instructed to walk as far as possible within six minutes (strokes of 30 meters of more).; The minimal age- and sex-specific normal 6MWD is defined as 82% of the applied reference equations for prediction of the 6MWD. The reference value that will be used is 6MWDpred(m) = 868.8 - (ageyears x 2.99) - (gender x 74.7). The value for gender is 0 in male subjects and 1 in female subjects.
Gait assessment: Functional ambulation categories	6 weeks, 3 months, 6 months, 9 months and 18 months (after randomization)	Functional ambulation categories (FAC) is a useful scale to assess gait in patients with foot drop. It is a six point scale, that is used in stroke literature and can help determine how much assistance a patient requires.; FAC 0 reflects a nonfunctional state and FAC 5 equals a normal gait pattern.
Patient-reported outcome measurements regarding health-related quality of life: 5 Level Euro Quality of Life 5 Dimensions (EQ5D-5L)	10 days (surgery), 6 weeks, 3 months, 6 months, 9 months and 18 months (after randomization)	The EQ-5D 5L is a generic measure of health-related quality of life developed by the EuroQol Group. It is a validated measurement of quality of life widely used in different pathologies. The questionnaire is made up of two parts. The first part is descriptive and uses five different dimensions to score quality of life. These five dimensions are mobility, self-care, activities of the daily life, pain/discomfort and anxiety/depression. There are five different answer possibilities within each dimension, i.e. "no problem", "slight problem", "moderate problem", "severe problem" and "unable to". This renders 3125 different answer possibilities. The second part uses a visual analogue scale (VAS) to score the current health status of the patient, ranging from zero to one hundred. Zero corresponds to death and one hundred corresponds to a (subjective) perfect health status.
Complications and neurologic deficits: Sensory changes	10 days (surgery), 6 weeks, 3 months, 6 months, 9 months and 18 months (after randomization))	In a large retrospective patient series on peroneal nerve decompression after weight loss, Broekx et al. (2018) examined the recovery of sensory deficits. Symptoms qualified as sensory included the presence of hypoesthesia and/or paresthesia. They used the following system to assess sensory symptoms: 1. Complete recovery: the absence of any sensory symptoms; 2. Partial recovery: patients with a minimum of sensory symptoms; 3. No recovery: patients with no improvement
Complications and neurologic deficits: Surgical complications	10 days, 6 weeks and 18 months after surgery	A list of possible complications is made available to all participating centers. Unforeseen complications will be recorded as free-text.
Gait assessment: The proportion of patients in both groups who reach minimal normal age- and sex-specific reference values for distance covered in meters during the six-minute walk test	9 months after randomization	The distance covered during the six-minute walk test (6MWT) is validated and clinically used in gait analysis.; 6MWT: patients are instructed to walk as far as possible within six minutes (strokes of 30 meters of more).; The minimal age- and sex-specific normal 6MWD is defined as 82% of the applied reference equations for prediction of the 6MWD. The reference value that will be used is 6MWDpred(m) = 868.8 - (ageyears x 2.99) - (gender x 74.7). The value for gender is 0 in male subjects and 1 in female subjects.
Health economic assessment: Return to work	6 weeks	Health economic aspects will also be evaluated through the assessment of return to work. We expect subgroups of patients with foot drop to be unable to work. Once the foot drop has improved (or fully recovered), we expect patients to be able to return to work and to not experience any more related problems (after their initial recovery). In this trial population foot drop does in general not represent a chronic condition with periods of relapse. Either the foot drop recovers enough to be able to work again, or the foot drop does not sufficiently recover to resume previous professional activities.; Taking this into account, return to work seems to represent a very important measure. Patients will be asked about return to work at the study visit six weeks after randomization. To avoid recall bias, patients will be asked in advance to record the date of return to work. During baseline assessments, subjects will be questioned if they are incapacitated to work due to the foot drop and the

Trial Locations

Locations (18)

Sint Augustinus; 🇧🇪 Wilrijk, Antwerpen, Belgium

Jessa Ziekenhuis; 🇧🇪 Hasselt, Limburg, Belgium

AZ Sint-Maarten; 🇧🇪 Mechelen, Antwerpen, Belgium

AZ Turnhout; 🇧🇪 Turnhout, Antwerpen, Belgium

AZ Vesalius; 🇧🇪 Tongeren, Limburg, Belgium

AZ Alma; 🇧🇪 Eeklo, Oost-Vlaanderen, Belgium

AZ Sint-Lucas; 🇧🇪 Gent, Oost-Vlaanderen, Belgium

AZ Sint-Jan; 🇧🇪 Brugge, West-Vlaanderen, Belgium

ULB Erasme, department of neurosurgery; 🇧🇪 Brussels, Belgium

Universitaire Ziekenhuizen Antwerpen; 🇧🇪 Antwerpen, Belgium

AZ Damiaan; 🇧🇪 Oostende, West-Vlaanderen, Belgium

AZ Groeninge, department of neurosurgery; 🇧🇪 Kortrijk, West-Vlaanderen, Belgium

UZ Brussel; 🇧🇪 Brussel, Belgium

Ziekenhuis Oost-Limburg, department of neurosurgery; 🇧🇪 Genk, Belgium

University Hospitals Of Leuven, department of neurosurgery; 🇧🇪 Leuven, Belgium

CHU de Liège, department of neurosurgery; 🇧🇪 Liège, Belgium

Leids Universitair Medisch Centrum, department of neurosurgery; 🇳🇱 Leiden, Netherlands

AZ Delta; 🇧🇪 Roeselare, West-Vlaanderen, Belgium